Statistiche di base
| LEI | 5493001KJQUA83L8MH79 |
| CIK | 1125345 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MacroGenics, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 14, 2025 |
Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. PURCHASE AND SALE AGREEMENT dated as of June 9, 2025 between MACROGENICS, INC. and SAGARD HEALTHCARE PARTNERS (DELAWARE) II LP Table of Contents Page ARTICLE I DEF |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Ex |
|
| August 14, 2025 |
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities Exhibit 99.1 MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities •Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 •Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® •Cash, cash equivalents and marketable securities of $176.5 million as |
|
| August 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 MACROGENICS, INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule(3) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share 457(c) and 457(h) 1,250,000(2) $1.5 |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 As filed with the Securities and Exchange Commission on August 14, 2025 Registration No. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 13, 2025 |
MacroGenics Appoints Eric Risser as President and Chief Executive Officer MacroGenics Appoints Eric Risser as President and Chief Executive Officer ROCKVILLE, MD, August 13, 2025 (GLOBE NEWSWIRE) - MacroGenics, Inc. |
|
| June 10, 2025 |
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement Exhibit 99.1 MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement •MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard) •MacroGenics’ cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on disco |
|
| June 10, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 22, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (E |
|
| May 13, 2025 |
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results •First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers •Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 •Advancement in portfol |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 20, 2025 |
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and 2024 Financial Results •Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC •Initiating new LINNET Phase 2 study of lorigerlimab in ovarian cancer •Advancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030 •Disc |
|
| March 20, 2025 |
aration and Consulting Agreement between the Company and Scott Koenig, M.D., Ph.D. Exhibit 10.36 AMENDMENT TO SEPARATION AND CONSULTING AGREEMENT This Amendment to Separation and Consulting Agreement (this "Amendment") is entered into on February 25, 2025, by and between MacroGenics, Inc. (the "Company"), and Dr. Scott Koenig ("you"). RECITALS WHEREAS, you and the Company previously entered into that certain Separation and Consulting Agreement dated October 25, 2024 (the "Agreem |
|
| March 20, 2025 |
between the Company and Scott Koe Exhibit.10.33 October 25, 2024 Scott Koenig 7109 Malibu Cove Austin, TX 78730 Dear Scott: This letter sets forth the substance of the separation agreement (the “Agreement”) that MacroGenics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.SEPARATION. Your last day of work with the Company and your employment termination date will be February 28, 2025 (the “Separatio |
|
| March 20, 2025 |
Exhibit 19.1 MACROGENICS, INC. INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) provides the standards of MacroGenics, Inc. and its affiliates (the "Company") for trading and causing the trading of the Company's securities or securities of other publicly-traded companies while in possession of confidential information. One of the purposes of the federal securities laws is to prohi |
|
| March 20, 2025 |
Exhibit.10.34 Amendment #1 Employment Agreement THIS AMENDMENT #1 (“Amendment”), effective as of January 1, 2025 (“Amendment Effective Date”), is by and between MacroGenics, Inc. (“Company”) and James Karrels (“Executive”) (each a “Party” and collectively the “Parties”). WHEREAS, Company and Executive executed an Employment Agreement effective on October 9, 2013 (“Agreement”); and WHEREAS, the Par |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36112 MACROGENICS, IN |
|
| March 20, 2025 |
ment Agreement between the Company and Stephen Eck, M.D., Exhibit.10.35 Amendment #1 Employment Agreement THIS AMENDMENT #1 (“Amendment”), effective as of January 1, 2025 (“Amendment Effective Date”), is by and between MacroGenics, Inc. (“Company”) and Stephen L. Eck, M.D., Ph.D. (“Executive”) (each a “Party” and collectively the “Parties”). WHEREAS, Company and Executive executed an Employment Agreement effective on July 1, 2020 (“Agreement”); and WHERE |
|
| March 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2025 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110255.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State |
|
| January 3, 2025 |
MacroGenics, Inc. 9704 Medical Center Drive Rockville, Maryland 20850 January 3, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Gordon Bonnie Baynes Re: MacroGenics, Inc. (the “Company”) Form 10-K for the Fiscal Year Ended December 31, 2023 Form 10-Q for the Quarterly Period Ended |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 18, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 20, 2024 |
EX-99.A 2 d881560dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of MacroGenics, Inc. Date: November 20, 2024 FRAZIER LIFE SCIENCES PUBLIC FUND, |
|
| November 20, 2024 |
MGNX / MacroGenics, Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment SC 13G 1 d881560dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* MacroGenics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) November 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| November 14, 2024 |
MGNX / MacroGenics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-mgnx093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* MACROGENICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 556099109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 5, 2024 |
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results •Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ® •ADAM9-directed ADC (MGC028) Investigational New Drug (IND) application submitted to FDA •Conference call sched |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC |
|
| November 5, 2024 |
Agreement by and between the Company and Exhibit 10.2 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. Execution Version August 30, 2024 Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 Ladies and Gentlemen: This second letter |
|
| November 5, 2024 |
Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. CONFIDENTIAL AMENDMENT NO. 4 TO GLOBAL COLLABORATION AND LICENSE AGREEMENT This Amendment No. 4 to Global Collaboration and License Agreem |
|
| November 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 30, 2024 |
Exhibit 99.1 MacroGenics Announces Leadership Transition • Scott Koenig, M.D., Ph.D., to step down as President and CEO • Board to initiate search process to identify new CEO ROCKVILLE, MD, OCT. 30, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for th |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 25, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 16, 2024 |
Exhibit 99.1 MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 •Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR •Patients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to |
|
| September 16, 2024 |
exhibit992postesmoconfca Developing Breakthrough Biologics, Life-changing Medicines® Post-ESMO Conference Call September 16, 2024 2 Legal Notices The information in this slide deck is current as of September 16, 2024, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC. |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Ex |
|
| August 6, 2024 |
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results •Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in September •Received $100.0 million in milestones related to Incyte’s advancement of ZYNYZ® (retifanlimab-dlwr) subsequent to quarter-end •Confirming cash runway guidance into 2026 ROCKVILLE, MD., Aug 6, |
|
| July 30, 2024 |
Exhibit 99.1 MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte •Confirming cash runway guidance into 2026 ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the tre |
|
| July 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 30, 2024 |
Exhibit 99.1 MacroGenics Provides Vobramitamab Duocarmazine Update •Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in September •ESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark primary endpoint of 6-month rPFS rate and updated safety •Treatment recently discontinued for TAMARACK mCRPC study participants who |
|
| July 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 4, 2024 |
MGNX / MacroGenics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MACROGENICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 556099109 (CUSIP Number) JUNE 3, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024 As filed with the Securities and Exchange Commission on May 23, 2024 Registration No. |
|
| May 23, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 23, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 MACROGENICS, INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule(3) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share 457(c) and 457(h) 2,000,000(2) $4.3 |
|
| May 21, 2024 |
MGNX / MacroGenics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 MGNXSC13GMay24.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MACROGENICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 556099109 (CUSIP Number) MAY 14, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the ru |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (E |
|
| May 9, 2024 |
Developing Breakthrough Biologics, Life-changing Medicines® Phase 2 Interim Data May 9, 2024 (Data Cut-off: April 12, 2024) 2 Legal Notices The information in this slide deck is current as of May 9, 2024, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC. |
|
| May 9, 2024 |
Exhibit 99.1 MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data •Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patients •Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, MD., May 9, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), |
|
| May 9, 2024 |
Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. EXECUTION VERSION FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT This First Amendment to the Collaboration and License Agreement (this “First Amendment |
|
| May 9, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 3, 2024 |
Exhibit 99.1 MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures •Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstract •Company plans to provide updated interim data, including safety and preliminary efficacy, by May 31 •Company plans to provide addi |
|
| April 3, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 7, 2024 |
MacroGenics.Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 MACROGENICS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY (Adopted November 30, 2023) 1.INTRODUCTION The Board of Directors (the “Board”) of MacroGenics, Inc., a Delaware corporation (the “Company”) has determined that it is in the best interests of the Company and its stockholders to adopt a policy (the “Policy”) providing for the Company’s recoupment of certain Incentive Compensati |
|
| March 7, 2024 |
Exhibit 10.10 MacroGenics, Inc. Stock Option Grant Notice (2023 Equity Incentive Plan) MacroGenics, Inc. (the “Company”), pursuant to its 2023 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein and in the P |
|
| March 7, 2024 |
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and 2023 Financial Results •Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024 •Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADC •Preclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and MGC028, |
|
| March 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 7, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 7, 2024 |
Exhibit 10.9 MacroGenics, Inc. RSU Award Grant Notice (2023 Equity Incentive Plan) MacroGenics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2023 Equi |
|
| March 7, 2024 |
Exhibit 10.11 MacroGenics, Inc. RSU Award Grant Notice (2023 Equity Incentive Plan) MacroGenics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2023 Equ |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36112 MACROGENICS, IN |
|
| March 7, 2024 |
Exhibit 10.8 MacroGenics, Inc. Stock Option Grant Notice (2023 Equity Incentive Plan) MacroGenics, Inc. (the “Company”), pursuant to its 2023 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein and in the Plan, |
|
| February 14, 2024 |
MGNX / MacroGenics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
MGNX / MacroGenics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MACROGENICS, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2024 |
Exhibit 1: Joint Filing Agreement EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L. |
|
| February 13, 2024 |
MGNX / MacroGenics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01383-macrogenicsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: MacroGenics Inc Title of Class of Securities: Common Stock CUSIP Number: 556099109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the |
|
| February 13, 2024 |
MGNX / MacroGenics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d771056dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| November 14, 2023 |
MacroGenics, Inc. 9704 Medical Center Drive Rockville, MD 20850 MacroGenics, Inc. 9704 Medical Center Drive Rockville, MD 20850 November 14, 2023 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes RE: MacroGenics, Inc. Registration Statement on Form S-3 File No. 333- 275343 Acceleration Request Requested Date: November 15, 2023 Requested Time: 4:00 p.m. Eastern |
|
| November 6, 2023 |
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results •Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule •Initiated LORIKEET Phase 2 study of lorigerlimab •Submitted IND for MGC026, a topoisomerase inhibitor-based ADC •Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, MD., Nov 6, 2023 (GLOBE NEWSWIRE) — Macr |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC |
|
| November 6, 2023 |
As filed with the Securities and Exchange Commission on November 6, 2023 As filed with the Securities and Exchange Commission on November 6, 2023 Registration No. |
|
| November 6, 2023 |
EXHIBIT 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT This Amendment No. 2 to the Asset Purchase Agreement (this “Amendment No. 2”), by and between MacroGenics, Inc., a Dela |
|
| November 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) MacroGenics, Inc. |
|
| October 30, 2023 |
MGNX / Macrogenics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm2329296d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MACROGENICS, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 556099109 (CUSIP Number) October 20, 2023 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| September 22, 2023 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 19, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Ex |
|
| August 9, 2023 |
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results •Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol •Initiating lorigerlimab Phase 2 study in mCRPC patients •Achieved $50 million milestone related to Sanofi’s announcement of positive top-line data from TZIELD® (tep |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 6, 2023 |
As filed with the Securities and Exchange Commission on June 6, 2023 As filed with the Securities and Exchange Commission on June 6, 2023 Registration No. |
|
| June 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 MACROGENICS, INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule(3) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(4) Equity Common Stock, $0.01 par value per share 457(c) and 457(h) 4,850,000(2) $ |
|
| June 6, 2023 |
3 Equity Incentive Plan (incorporated by reference to Exhibit Exhibit 99.1 MacroGenics, Inc. 2023 Equity Incentive Plan 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve plus any Returning Shares will become available for issuance pursuant to Awards granted un |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2023 |
Purchase and Sale Agreement by and between the Company and DRI Healthcare Acquisitions LP, dated M Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. PURCHASE AND SALE AGREEMENT dated as of March 8, 2023 between MACROGENICS, INC. and DRI HEALTHCARE ACQUISITIONS LP TABLE OF CONTENTS Page ARTICLE I DEFINED TERMS A |
|
| May 9, 2023 |
MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results •ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipeline •Multiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC) •Cash runway through 2025 with $270 million in non-dilutive funding achieved over past nine months •Conference call |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (E |
|
| April 19, 2023 |
DEFA14A 1 defa14a2023.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission O |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 24, 2023 |
Exhibit 99.1 MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr) Rockville, MD. March 22, 2023 (GLOBE NEWSWIRE) – MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration’ |
|
| March 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 15, 2023 |
Exhibit.10.27 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is entered into as of this [***] day of [***], [***] (the “Execution Date”), by |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
Exhibit 10.22 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT between MACROGENICS, INC. and Gilead Sciences, Inc. dated October 14, 2022 TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. OVERVIEW |
|
| March 15, 2023 |
Exhibit.10.26 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of this [***]day of [***] March, 2014, by and between BMR-MEDICAL CEN |
|
| March 15, 2023 |
MacroGenics Provides Corporate Update and 2022 Financial Results Exhibit 99.1 MacroGenics Provides Corporate Update and 2022 Financial Results •Cash runway extended through 2025 with $250 million in non-dilutive funding over past eight months •TAMARACK study design modified with objective of accelerating data readout •Encouraging lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) monotherapy clinical data presented at ASCO-GU •Conference call scheduled for |
|
| March 15, 2023 |
Exhibit.10.24 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT This Amendment No. 1 to the Asset Purchase Agreement (this “Amendment No. 1”), by and between MacroGenics, Inc., a Del |
|
| March 15, 2023 |
Exhibit.10.28 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is entered into as of this [***] day of [***], [***] (the “Third Amendment Executi |
|
| March 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Macrogenics, Inc. |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 MACROGENICS, INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule(3) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(4) Equity Common Stock, $0.01 par value per share 457(h) 1,960,168(2) $5.67(3) $11 |
|
| March 15, 2023 |
MacroGenics, Inc. $100,000,000 Common Stock SALES AGREEMENT Exhibit 1.2 MacroGenics, Inc. $100,000,000 Common Stock SALES AGREEMENT March 15, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: MacroGenics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to |
|
| March 15, 2023 |
Exhibit.10.30 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this [***], [***] (“Execution Date”), by and between ARE-MARYLAND |
|
| March 15, 2023 |
Exhibit 10.23 CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to denote where omissions have been made. The confidential material has been filed separately with the Securities and Exchange Commission. ASSET PURCHASE AGREEMENT This Asset Purchas |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36112 MACROGENICS, IN |
|
| March 15, 2023 |
Exhibit.10.29 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this [***] day of [***] (the “Execution Date”), by and between B |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
Exhibit.10.25 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. LEASE THIS LEASE (this “Lease”) is entered into as of this [***] day of [***] (the “Execution Date”), by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limi |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 9, 2023 |
Exhibit 99.1 MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million Rockville, Md. March 8, 2023 – MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has entered into an agreement to sell its royalty interest on future gl |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 14, 2023 |
MGNX / MacroGenics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d401652dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| February 14, 2023 |
Exhibit 99.1 MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium •Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (2 |
|
| February 14, 2023 |
EX-99.B 2 d401652dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
MGNX / MacroGenics Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-mgnx123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MACROGENICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 14, 2023 |
MGNX / MacroGenics Inc / RTW INVESTMENTS, LP - MACROGENICS, INC. Passive Investment SC 13G/A 1 p23-0691sc13ga.htm MACROGENICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Macrogenics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the app |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 9, 2023 |
MGNX / MacroGenics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01349-macrogenicsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: MacroGenics Inc. Title of Class of Securities: Common Stock CUSIP Number: 556099109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate th |
|
| January 18, 2023 |
MGNX / MacroGenics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 MGNXSC13GA12023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MACROGENICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 556099109 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropria |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2023 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 5, 2023 |
Exhibit 99.1 MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors ROCKVILLE, MD, January 4, 2023 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 19, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 16, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 18, 2022 |
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab Exhibit 99.1 MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab ROCKVILLE, MD., November 17, 2022 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of t |
|
| November 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 17, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC |
|
| November 3, 2022 |
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results Exhibit 99.1 MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results ?Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced ?Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-end ?Anticipated update on lorigerlimab (PD-1 ? CTLA-4 bispecific DART? molecule) monotherapy clinical data in first quarter of |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 3, 2022 |
Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NO. 3 TO GLOBAL COLLABORATION AND LICENSE AGREEMENT This Amendment No. 3 to Global Collaboration and License Agreement (this ?Amendment No. 3?) is dated |
|
| October 17, 2022 |
Exhibit 99.1 Gilead Contacts: MacroGenics Contact: Jacquie Ross, Investors Jim Karrels, Senior Vice President, CFO [email protected] [email protected] Marian Cutler, Media [email protected] GILEAD AND MACROGENICS ANNOUNCE ONCOLOGY COLLABORATION TO DEVELOP BISPECIFIC ANTIBODIES – Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123×CD3 DART® Molecule with Potenti |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 2, 2022 |
MGNX / MacroGenics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MACROGENICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 556099109 (CUSIP Number) AUGUST 25, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this |
|
| August 15, 2022 |
MGNX / MacroGenics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* MACROGENICS, INC (Name of Issuer) Common Shares, par value $0.01 per share (Title of Class of Securities) 556099109 (CUSIP Number) August 15, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| August 8, 2022 |
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results ?First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignancies ?Plan to initiate MGC018 Phase 2/3 study in prostate cancer by year-end ?Initiates cost-saving measures through corporate restructuring with focus on key clinical programs, extending cash runway into 2024 |
|
| August 8, 2022 |
Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY [***]) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NO. 2 TO GLOBAL COLLABORATION AND LICENSE AGREEMENT This Amendment No. 2 to Global Collaboration and License Agreement (this "Amendment No. 2") is dated |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Ex |
|
| July 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 8, 2022 |
Exhibit 99.1 MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer ROCKVILLE, MD, July 08, 2022 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of Ju |
|
| May 24, 2022 |
MacroGenics Announces Appointment of William Heiden to Board of Directors Exhibit 99.1 MacroGenics Announces Appointment of William Heiden to Board of Directors ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of William Heiden to its Board of Directors, effective May 22, |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (E |
|
| May 3, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into as of November 1, 2019 (the ?Effective Date?), by and between MacroGenics, Inc., a Delaware corporation, together with its successors and assigns (the ?Employer'' or ?Company?), and Thomas Spitznagel (?Executive?). In consideration of the promises and the respective undertakings of Employer and Executive |
|
| May 3, 2022 |
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results ?Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end ?Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors ?Targeting mid-2022 start of Phase 1 study of MGD024 in hematologic malignancies ?Conference call scheduled for today at?4:30 p.m. E |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 24, 2022 |
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and 2021 Financial Results ?Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeks ?Prioritizing MGD024 as lead CD3-based DART? molecule targeting CD123 and discontinuing development of flotetuzumab ?Presented encouraging preclinical combinatorial anti-tumor activity with M |
|
| February 24, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 MACROGENICS, INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule(3) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(4) Equity Common Stock, $0.01 par value per share 457(h) 1,960,168(2) $10.14(3) $1 |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36112 MACROGENICS, IN |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 14, 2022 |
MGNX / MacroGenics Inc / RTW INVESTMENTS, LP - MACROGENICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Macrogenics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 14, 2022 |
MGNX / MacroGenics Inc / RA CAPITAL MANAGEMENT, L.P. - MACROGENICS INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MACROGENICS, INC (Name of Issuer) Common Shares, par value $0.01 per share (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 11, 2022 |
MGNX / MacroGenics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 10, 2022 |
MGNX / MacroGenics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01356-macrogenicsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: MacroGenics Inc. Title of Class of Securities: Common Stock CUSIP Number: 556099109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate th |
|
| January 31, 2022 |
MGNX / MacroGenics Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* MacroGenics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2022 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 2, 2021 |
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results ?Investigational New Drug (IND) application submitted for MGD024, a next generation DART? molecule targeting CD123 and CD3 for AML ?U.S. Food & Drug Administration (FDA) approves MacroGenics? GMP manufacturing facility to produce MARGENZA? drug substance ?Discontinuing enrollment of Cohort A of |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 16, 2021 |
Exhibit 99.2 MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress ?Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ? 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor activity; 4 of 16 (25%) achieved pa |
|
| September 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 16, 2021 |
Exhibit 99.1 MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021 ?21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A ?78% of patients had tumor sh |
|
| September 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 8, 2021 |
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA? in Patients with HER2-Positive Metastatic Breast Cancer ?Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab ?OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy arm, while the OS for trastuzumab plus chemotherapy was greater than MARGENZA plus chemotherapy for the small exploratory subgroup of patients homozygous for the CD16A 158V allele ?The safety profile remains similar to what has been reported previously ROCKVILLE, MD, Sept. |
|
| July 29, 2021 |
Stock Purchase Agreement by and between the Company and Zai Lab Limited, dated June 14, 2021 Exhibit 10.2 STOCK PURCHASE AGREEMENT By and Between ZAI LAB LIMITED AND MACROGENICS, INC. Dated as of June 14, 2021 TABLE OF CONTENTS 1......... Definitions.......................................................................................................................... 1 1.1...... Defined Terms............................................................................................... |
|
| July 29, 2021 |
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results ?Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) Meeting ?Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, MD., July 29, 2021 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company foc |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Ex |
|
| July 29, 2021 |
Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY ***) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (?Agreement?), effective as of June 15, 2021 (the ?Effective Date?), is entered into by |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 16, 2021 |
Exhibit 99.1 MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology ?Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules ?MacroGenics provides rights to Zai Lab for its DART? and TRIDENT? multi-specific platforms and a lead research program targeti |
|
| June 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 11, 2021 |
MGNX / MacroGenics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) June 9, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| May 18, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (E |
|
| April 29, 2021 |
MACROGENICS, INC. Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-249851 PROSPECTUS SUPPLEMENT (To Prospectus dated November 4, 2020) $200,000,000 MACROGENICS, INC. Common Stock We have entered into a sales agreement, or Sales Agreement, with Cowen and Company, LLC, or Cowen, dated November 4, 2020, and amended on April 29, 2021, relating to shares of our common stock offered by this prosp |
|
| April 29, 2021 |
Employment Agreement between the Company and Stephen Eck, M.D. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into as of July 1, 2020 (the ?Effective Date?), by and between MacroGenics, Inc., a Delaware corporation, together with its successors and assigns (the ?Employer? or ?Company?), and Stephen L. Eck (?Executive?). In consideration of the promises and the respective undertakings of Employer and Executive set fort |
|
| April 29, 2021 |
MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results ?MARGENZA? launched in mid-March ?Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCO ?Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, MD., April 29, 2021 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developi |
|
| April 29, 2021 |
MACROGENICS, INC. AMENDMENT NO. 1 TO SALES AGREEMENT EX-1.2 2 nt10023799x2ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 MACROGENICS, INC. AMENDMENT NO. 1 TO SALES AGREEMENT April 29, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Reference is made to the Sales Agreement, dated as of November 4, 2020 (the “Sales Agreement”), between Cowen and Company, LLC (“Cowen”) and MacroGenics, Inc., a Delaware corporation (the “Com |
|
| April 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 2, 2021 |
Amended and Restated By-Laws of the Company Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF MACROGENICS, INC. A DELAWARE CORPORATION Dated: March 30, 2021 TABLE OF CONTENTS ARTICLE I STOCKHOLDERS 1.1 Place of Meetings 1.2 Annual Meeting 1.3 Special Meetings 1.4 Notice of Meetings 1.5 Voting List 1.6 Quorum 1.7 Adjournments 1.8 Voting and Proxies 1.9 Action at Meeting 1.10 Nomination of Directors 1.11 Notice of Business at Annual Meetings 1.12 C |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 25, 2021 |
Commercial Supply Agreement by and between Exhibit 10.15 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]?. CONFIDENTIAL EXECUTION COPY COMMERCIAL SUPPLY AGREEMENT BETWEEN CMC ICOS BIOLOGICS, INC. and MACROGENICS, INC. 244238347 v3 Commercial Supply Agr |
|
| February 25, 2021 |
EX-4.2 2 mgnxexhibit4-2202010xk.htm EX-4.2 Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, MacroGenics, Inc. (“we”, “our” and “us”), has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, par value of $0.01 per share (Common Stock). The following desc |
|
| February 25, 2021 |
Product Commercialization Agreement by and between the Company and Eversana Life Science Service Exhibit 10.17 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]?. EXECUTION VERSION CONFIDENTIAL PRODUCT COMMERCIALIZATION AGREEMENT This Product Commercialization Agreement (this ?Agreement?) is made on Novembe |
|
| February 25, 2021 |
Commercial Supply Agreement by and between Incyte Corporation and the Company, dated Exhibit 10.16 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]?. COMMERCIAL SUPPLY AGREEMENT This Commercial Supply Agreement (the ?Agreement?) is entered into as of September 30, 2020 (?Effective Date?), by an |
|
| February 25, 2021 |
As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 25, 2021 |
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and 2020 Financial Results ?MARGENZA? approved in December 2020; commercial launch expected March 2021 ?July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumab ?Multiple clinical updates across portfolio anticipated in 2021 ?Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, MD, February 25, |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36112 MACROGENICS, IN |
|
| February 16, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) MacroGenics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.01 Per Sh |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MACROGENICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MacroGenics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* MACROGENICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 556099109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) MACROGENICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 556099109 (CUSIP Number) DECEMBER 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pu |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2021 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 11, 2021 |
Exhibit 99.1 MacroGenics Names Federica O’Brien to its Board of Directors ROCKVILLE, MD, Feb 11, 2021 (GLOBE NEWSWIRE) - MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Freddi” O’Brien, President of CFO’Brien Consulting, |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: MacroGenics Inc. Title of Class of Securities: Common Stock CUSIP Number: 556099109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| December 16, 2020 |
EX-99.1 2 margenzaapprovalpressrelea.htm EX-99.1 Exhibit 99.1 MacroGenics Announces FDA Approval of MARGENZATM for Patients with Pretreated Metastatic HER2-Positive Breast Cancer •MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial |
|
| December 16, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 30, 2020 |
Exhibit 99.1 MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab •MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expenses •EVERSANA may earn revenue share payments over five years subject to predefined cap •MacroGenics’ projected cash runway remains into 2023 ROCKVILLE, MD and CHICAGO, IL, |
|
| November 30, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 25, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 4, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 4, 2020 Registration No. |
|
| November 4, 2020 |
MACROGENICS, INC. $100,000,000 COMMON STOCK SALES AGREEMENT EX-1.2 2 nt10016582x1ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 MACROGENICS, INC. $100,000,000 COMMON STOCK SALES AGREEMENT November 4, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: MacroGenics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of S |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC |
|
| November 4, 2020 |
EX-99.1 2 exhibit99-1earningspre.htm EX-99.1 Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results –Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, MD., November 4, 2020 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody |
|
| October 16, 2020 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 13, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 21, 2020 |
EX-99.1 2 p13gb.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of |
|
| August 21, 2020 |
MGNX / MacroGenics, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) MacroGenics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.01 Per Shar |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Ex |
|
| July 31, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 31, 2020 |
Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results –Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, MD., July 30, 2020 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer |
|
| June 19, 2020 |
$125,000,000 MACROGENICS, INC. Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) File No. 333-235691 PROSPECTUS SUPPLEMENT (To Prospectus dated January 3, 2020) $125,000,000 MACROGENICS, INC. Common Stock We have entered into a sales agreement, or Sales Agreement, with Cowen and Company, LLC, or Cowen, dated December 23, 2019, and amended on June 19, 2020, relating to shares of our common stock offered by this prospectus s |
|
| June 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 19, 2020 |
MACROGENICS, INC. AMENDMENT NO. 1 TO SALES AGREEMENT EX-1.2 2 nt10012941x2ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 MACROGENICS, INC. AMENDMENT NO. 1 TO SALES AGREEMENT June 19, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Reference is made to the Sales Agreement, dated as of December 23, 2019 (the “Sales Agreement”), between Cowen and Company, LLC (“Cowen”) and MacroGenics, Inc., a Delaware corporation (the “Com |
|
| June 18, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 18, 2020 |
MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer EX-99.1 2 exhibit991dreck.htm EX-99.1 Exhibit 99.1 MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer Rockville, MD, June 16, 2020 (GLOBE NEWSWIRE) – MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Stephen Ec |
|
| May 29, 2020 |
EX-99.2 3 asco2020mgc018phase1.htm ASCO 2020 MGC018 PHASE 1 Preliminary Dose Escalation Results from a Phase 1/2, First-in-Human Study of Abstract #308859 MGC018 (Anti-B7-H3 Antibody-Drug Conjugate) in Patients with Advanced Solid Tumors John Powderly1, Sekwon Jang2, Juniper Scribner3, Deryk Loo3, Chet Bohac3, Alexander Spira4, Manish Sharma5 NCT03729596 1Carolina BioOncology, Huntersville, NC; 2I |
|
| May 29, 2020 |
asco2020sophiabychemo SOPHIA Analysis by Chemotherapy (Ctx) Choice: A Phase 3 (P3) Study of Margetuximab (M) + Ctx vs Abstract #1040 Trastuzumab (T) + Ctx in Patients (pts) with Pretreated HER2+ Metastatic (met) Breast Cancer (MBC) Santiago Escriva-de-Romani, MD1, Seock-Ah Im, MD, PhD2, Fatima Cardoso, MD3, Javier Cortes, MD, PhD4, Giuseppe Curigliano, MD, PhD5, William J. |
|
| May 29, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 29, 2020 |
asco2020mgd013phase1 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms Jason J. |
|
| May 14, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 13, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 13, 2020 |
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting Rockville, MD, May 13, 2020 (GLOBE NEWSWIRE) – MacroGenics, Inc. |
|
| May 5, 2020 |
Amendment No.1 to Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. AMENDMENT #1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT #1 ("Amendment"), effective as of September 24, 2019 ("Amendment Effective Date"), is by and between MacroGenics, Inc. |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (E |
|
| May 5, 2020 |
Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results –Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, MD., May 5, 2020 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, t |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2020 |
MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format EX-99.1 2 exhibit991virtualmeeti.htm EX-99.1 MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that its 2020 Annual Me |
|
| April 28, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2020 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
